Jun 2026 (Q2 FY26) — Aug 6, 2026
AVITA Medical Q2 FY26 — Record Revenue and Path to Cash Flow Breakeven
Read the full callAVITA Medical (RCEL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AVITA Medical earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 21.7 | +17.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -31.6 | +28.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$13.41 +2.37% · +$0.31
Performance +154.5% 1Y
1Y: $5.27 on 14 Oct 2025 → $13.41. High $13.41 (15 Oct 2026), low $3.27 (17 Dec 2025).
- Previous close
- $13.1
- 52-week range
- $3.27 – $13.41
- One year
- +151.59%
Overview
- Symbol
- RCEL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AVITA Medical earnings calls (RCEL)
Financials
What the filings say
Net profit, year on year: +23% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 18 | 19 | 18 | 17 | 18 | 19 | 22 |
| Operating profit | -14 | -10 | -12 | -11 | -9 | -10 | -9 | -7 |
| Operating margin | −70.6% | −54.1% | −63.9% | −60.5% | −53.6% | −59.1% | −45.7% | −31.6% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -16 | -12 | -14 | -10 | -13 | -12 | -11 | -8 |
| Tax rate | 0.2% | −0.2% | −0.1% | −0.0% | −0.1% | 0.1% | 0.1% | −0.4% |
| Net profit | -16 | -12 | -14 | -10 | -13 | -12 | -11 | -8 |
| EPS ($ per share) | -0.62 | — | -0.53 | -0.38 | -0.46 | — | -0.35 | -0.25 |
| Line item | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -153 | -195 | -221 | -263 | -298 | -360 | -408 |
| Total liabilities | — | 5 | 10 | 10 | 13 | 62 | 75 | 73 |
| Fixed assets | — | 1 | 1 | 1 | 1 | 2 | 10 | 9 |
| Investments | — | — | — | — | 61 | 67 | 22 | 8 |
| Total assets | — | 26 | 82 | 126 | 98 | 112 | 80 | 56 |
| Line item | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13 | -19 | -23 | -26 | -19 | -38 | -49 | -31 |
| Cash from investing | -0 | -1 | -1 | -1 | -19 | 2 | 37 | 12 |
| Cash from financing | 21 | 30 | 77 | 64 | 1 | 40 | 4 | 15 |
| Net cash flow | 8 | 9 | 53 | 37 | -38 | 4 | -8 | -4 |
| Capital expenditure | -0 | -1 | -1 | -1 | -0 | -1 | -9 | -1 |
| Free cash flow | -13 | -20 | -23 | -27 | -20 | -39 | -58 | -32 |
Insider filings
25 filings between Jan 5, 2026 and Jun 12, 2026.
Open market
decisions to buy or sellPurchases
$234.6K
14 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 11
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Woody Joseph Fralin | $188.6K | — | Jun 9, 2026 |
| O'Toole David D | $46.0K | — | Jun 12, 2026 |
Latest filings (45)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | O'Toole David D CFO | Purchase | 2,000 | $7.9K |
| Jun 9, 2026 | Woody Joseph Fralin Director | Purchase | 5,200 | $20.8K |
| Jun 9, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $20.9K |
| Jun 9, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $21.0K |
| Jun 3, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $20.4K |
| Jun 3, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $20.5K |
| Jun 2, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $21.0K |
| Jun 2, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $20.9K |
| Jun 1, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $21.7K |
| Jun 1, 2026 | Woody Joseph Fralin Director | Purchase | 5,000 | $21.3K |
| May 29, 2026 | O'Toole David D CFO | Award | 5,000 | $15.3K |
| May 29, 2026 | Vance Cary Guy President and CEO | Award | 5,000 | $15.3K |
| May 20, 2026 | O'Toole David D CFO | Purchase | 2,000 | $8.5K |
| May 19, 2026 | O'Toole David D CFO | Purchase | 2,000 | $8.5K |
| Mar 11, 2026 | O'Toole David D CFO | Purchase | 1,800 | $8.6K |
| Feb 19, 2026 | O'Toole David D CFO | Purchase | 3,000 | $12.5K |
| Feb 18, 2026 | O'Toole David D CFO | Award | 105,470 | — |
| Feb 18, 2026 | KELSEY NICOLE Chief Legal Officer | Award | 98,390 | — |
| Jan 20, 2026 | Crowe Suzanne Director | Award | 22,214 | — |
| Jan 20, 2026 | REED JAN STERN Director | Award | 22,214 | — |
| Jan 20, 2026 | COOK JEREMY CURNOCK Director | Award | 22,214 | — |
| Jan 20, 2026 | McNamara Robert Director | Award | 22,214 | — |
| Jan 20, 2026 | Tarnoff Michael E Director | Award | 22,214 | — |
| Jan 20, 2026 | Woody Joseph Fralin Director | Award | 22,214 | — |
| Jan 5, 2026 | Woody Joseph Fralin Director | Award | 40,547 | — |
| Aug 28, 2025 | McNamara Robert Director | Purchase | 10,000 | $45.0K |
| Aug 26, 2025 | O'Toole David D CFO | Purchase | 2,000 | $9.0K |
| Aug 19, 2025 | McNamara Robert Director | Purchase | 10,000 | $50.0K |
| Aug 12, 2025 | O'Toole David D CFO | Purchase | 2,000 | $9.6K |
| Aug 6, 2025 | Tarnoff Michael E Director | Award | 26,250 | — |
| May 30, 2025 | O'Toole David D CFO | Award | 1,923 | $9.2K |
| Mar 6, 2025 | McNamara Robert Director | Purchase | 11,000 | $91.3K |
| Feb 20, 2025 | McNamara Robert Director | Purchase | 10,000 | $100.9K |
| Feb 20, 2025 | O'Toole David D CFO | Purchase | 1,000 | $9.9K |
| Feb 19, 2025 | O'Toole David D CFO | Purchase | 1,000 | $10.3K |
| Jan 21, 2025 | REED JAN STERN Director | Award | 10,022 | — |
| Jan 21, 2025 | Panaccio Lou Director | Award | 10,022 | — |
| Jan 21, 2025 | Crowe Suzanne Director | Award | 10,022 | — |
| Jan 21, 2025 | COOK JEREMY CURNOCK Director | Award | 10,022 | — |
| Jan 21, 2025 | McNamara Robert Director | Award | 10,022 | — |
| Jan 21, 2025 | Vance Cary Guy Director | Award | 10,022 | — |
| Dec 9, 2024 | Crowe Suzanne Director | Purchase | 486 | $6.4K |
| Dec 5, 2024 | O'Toole David D CFO | Purchase | 475 | $6.0K |
| Dec 5, 2024 | O'Toole David D CFO | Purchase | 500 | $6.2K |
| Nov 29, 2024 | O'Toole David D CFO | Award | 785 | $6.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AVITA Medical, Inc.
Free account. Everything above stays public.
Write why you follow AVITA Medical, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading